Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22)

Chih Cheng Chen, Jyh Pyng Gau, An Bin Yu, Chang Hsien Lu, Kuan Der Lee, Jie Yu You

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined. This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change. A total of 22 patients with AML with t(8;21)(q22;q22) were studied. Various parameters were tested for their impact on disease-free survival (DFS) and overall survival (OS). Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes. Between patients with t(8;21) and those with a normal karyotype, no significant differences were noted in DFS (median survival, 15.23 vs 12.03 mo; P=.7626) and OS (median survival, 19.17 vs 18.93 mo; P=.7543). Among t(8;21)(q22;q22) patients, no clinical parameters showed a significant impact on DFS. Univariate analysis revealed that a higher platelet count (>15·10 9/L) at diagnosis, a low white blood cell count (index ≤20), and hematopoietic stem cell transplantation (HSCT) as postremission therapy were associated with improved OS. On multivariate analysis, HSCT as postremission therapy and white blood cell count index <20 remained good independent prognostic factors for OS. The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes. It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.

Original languageEnglish
Pages (from-to)907-920
Number of pages14
JournalAdvances in Therapy
Volume24
Issue number4
DOIs
Publication statusPublished - Jul 2007
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Karyotype
Survival
Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Leukocyte Count
Cytogenetics
Therapeutics
Platelet Count
Multivariate Analysis

Keywords

  • Acute myeloid leukemia
  • Hematopoietic stem cell transplantation
  • Prognosis
  • t(8;21)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). / Chen, Chih Cheng; Gau, Jyh Pyng; Yu, An Bin; Lu, Chang Hsien; Lee, Kuan Der; You, Jie Yu.

In: Advances in Therapy, Vol. 24, No. 4, 07.2007, p. 907-920.

Research output: Contribution to journalArticle

Chen, Chih Cheng ; Gau, Jyh Pyng ; Yu, An Bin ; Lu, Chang Hsien ; Lee, Kuan Der ; You, Jie Yu. / Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). In: Advances in Therapy. 2007 ; Vol. 24, No. 4. pp. 907-920.
@article{ddbec3742569470688b08dc5a4c29f13,
title = "Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22)",
abstract = "Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined. This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change. A total of 22 patients with AML with t(8;21)(q22;q22) were studied. Various parameters were tested for their impact on disease-free survival (DFS) and overall survival (OS). Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes. Between patients with t(8;21) and those with a normal karyotype, no significant differences were noted in DFS (median survival, 15.23 vs 12.03 mo; P=.7626) and OS (median survival, 19.17 vs 18.93 mo; P=.7543). Among t(8;21)(q22;q22) patients, no clinical parameters showed a significant impact on DFS. Univariate analysis revealed that a higher platelet count (>15·10 9/L) at diagnosis, a low white blood cell count (index ≤20), and hematopoietic stem cell transplantation (HSCT) as postremission therapy were associated with improved OS. On multivariate analysis, HSCT as postremission therapy and white blood cell count index <20 remained good independent prognostic factors for OS. The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes. It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.",
keywords = "Acute myeloid leukemia, Hematopoietic stem cell transplantation, Prognosis, t(8;21)",
author = "Chen, {Chih Cheng} and Gau, {Jyh Pyng} and Yu, {An Bin} and Lu, {Chang Hsien} and Lee, {Kuan Der} and You, {Jie Yu}",
year = "2007",
month = "7",
doi = "10.1007/BF02849984",
language = "English",
volume = "24",
pages = "907--920",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "4",

}

TY - JOUR

T1 - Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22)

AU - Chen, Chih Cheng

AU - Gau, Jyh Pyng

AU - Yu, An Bin

AU - Lu, Chang Hsien

AU - Lee, Kuan Der

AU - You, Jie Yu

PY - 2007/7

Y1 - 2007/7

N2 - Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined. This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change. A total of 22 patients with AML with t(8;21)(q22;q22) were studied. Various parameters were tested for their impact on disease-free survival (DFS) and overall survival (OS). Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes. Between patients with t(8;21) and those with a normal karyotype, no significant differences were noted in DFS (median survival, 15.23 vs 12.03 mo; P=.7626) and OS (median survival, 19.17 vs 18.93 mo; P=.7543). Among t(8;21)(q22;q22) patients, no clinical parameters showed a significant impact on DFS. Univariate analysis revealed that a higher platelet count (>15·10 9/L) at diagnosis, a low white blood cell count (index ≤20), and hematopoietic stem cell transplantation (HSCT) as postremission therapy were associated with improved OS. On multivariate analysis, HSCT as postremission therapy and white blood cell count index <20 remained good independent prognostic factors for OS. The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes. It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.

AB - Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined. This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change. A total of 22 patients with AML with t(8;21)(q22;q22) were studied. Various parameters were tested for their impact on disease-free survival (DFS) and overall survival (OS). Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes. Between patients with t(8;21) and those with a normal karyotype, no significant differences were noted in DFS (median survival, 15.23 vs 12.03 mo; P=.7626) and OS (median survival, 19.17 vs 18.93 mo; P=.7543). Among t(8;21)(q22;q22) patients, no clinical parameters showed a significant impact on DFS. Univariate analysis revealed that a higher platelet count (>15·10 9/L) at diagnosis, a low white blood cell count (index ≤20), and hematopoietic stem cell transplantation (HSCT) as postremission therapy were associated with improved OS. On multivariate analysis, HSCT as postremission therapy and white blood cell count index <20 remained good independent prognostic factors for OS. The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes. It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.

KW - Acute myeloid leukemia

KW - Hematopoietic stem cell transplantation

KW - Prognosis

KW - t(8;21)

UR - http://www.scopus.com/inward/record.url?scp=38449088147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449088147&partnerID=8YFLogxK

U2 - 10.1007/BF02849984

DO - 10.1007/BF02849984

M3 - Article

VL - 24

SP - 907

EP - 920

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 4

ER -